You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 8,129,352


✉ Email this page to a colleague

« Back to Dashboard


Title:Antisense antiviral compound and method for treating ssRNA viral infection
Abstract: The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Flaviviridae, Picornoviridae, Caliciviridae, Togaviridae, Arteriviridae, Coronaviridae, Astroviridae and Hepeviridae families in the treatment of a viral infection. The antisense antiviral compounds are substantially uncharged morpholino oligonucleotides having a sequence of 12-40 subunits, including at least 12 subunits having a targeting sequence that is complementary to a region associated with stem-loop secondary structure within the 5'-terminal end 40 bases of the positive-sense RNA strand of the virus.
Inventor(s): Iversen; Patrick L. (Corvallis, OR), Stein; David A. (Corvallis, OR)
Assignee: AVI BioPharma, Inc. (Corvallis, OR)
Filing Date:Sep 14, 2005
Application Number:11/226,995
Claims:1. A method of inhibiting replication of a Flaviviridae positive strand RNA virus selected from yellow fever virus, Dengue virus, tick born encephalitis virus, and West Nile virus, comprising: administering to mammalian host cells a virus-inhibitory amount of an antisense oligonucleotide analog characterized by (i) a nuclease-resistant backbone, (ii) being capable of uptake by mammalian host cells, (iii) containing up to 25 nucleotide bases, (iv) being composed of morpholino subunits linked by phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5' exocyclic carbon of an adjacent subunit, and (v) having a targeting sequence that comprises the sequence set forth in SEQ ID NO:47, 49, 51, or 55, wherein the antisense oligonucleotide analog disrupts a stem-loop structure in the 5'-terminal region of the RNA virus and inhibits virus production.

2. The method of claim 1, wherein the heteroduplex has a Tm of dissociation of at least 45.degree. C.

3. The method of claim 1, wherein the intersubunit linkages are uncharged.

4. The method of claim 1, wherein the morpholino subunits are joined by intersubunit linkages, in accordance with the structure: ##STR00005## where Y.sub.1=O, Z=O, Pj is a purine or pyrimidine base-pairing moiety effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide; and X is alkyl, alkoxy, thioalkoxy; or --NR.sub.2, where each R is independently hydrogen or lower alkyl.

5. The method of claim 4, wherein X is --NR.sub.2, wherein R is independently hydrogen or methyl.

6. The method of claim 1, wherein the antisense oligonucleotide is attached to an arginine-rich polypeptide effective to enhance the uptake of the compound into host cells.

7. The method of claim 6, wherein the arginine-rich polypeptide has the sequence of SEQ ID NO: 122.

8. The method of claim 1, wherein the administration is to a mammalian subject in a therapeutically effective amount to treat a Flaviviridae virus infection.

9. The method of claim 8, wherein the Flaviviridae virus is Dengue virus.

10. The method of claim 1, wherein the administration is by intravenous or oral administration.

11. The method of claim 1, wherein the antisense oligonucleotide analog administered is contained in a cocktail of antisense oligonucleotides directed against two or more Flaviviridae positive-strand RNA viruses.

12. A method of treating an infection by a Flaviviridae positive strand RNA virus selected from yellow fever virus, Dengue virus, tick born encephalitis virus, and West Nile virus, comprising: administering to a subject a therapeutically effective amount of an antisense morpholino oligonucleotide, wherein the morpholino oligonucleotide has (i) a targeting sequence that comprises the sequence set forth in SEQ ID NO: 47, 49, 51, or 55, (ii) a subunit length of up to 25 subunits, wherein morpholino subunits of the oligomer are joined by intersubunit linkages in accordance with the structure: ##STR00006## wherein Y.sub.1=O, Z=O, Pj is a purine or pyrimidine base-pairing moiety effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide; and X is --NR.sub.2, where each R is independently hydrogen or methyl; and wherein the antisense morpholino oligomer forms a heteroduplex with the target region to disrupt the stem loop structure and inhibit Flaviviridae virus production.

13. The method of claim 12, wherein the Flaviviridae virus is a Dengue virus and the targeting sequence comprises SEQ ID NO:51.

14. The method of claim 12, wherein the Flaviviridae is a yellow fever virus and the targeting sequence comprises SEQ ID NO:49.

15. The method of claim 12, wherein the Flaviviridae is a tick borne encephalitis virus and the targeting sequence comprises SEQ ID NO:55.

16. The method of claim 12, wherein the Flaviviridae is a West Nile virus and the targeting sequence comprises SEQ ID NO:47.

17. The method of claim 13, wherein the antisense oligonucleotide has a subunit length of about 22 subunits.

18. The method of claim 17, wherein the antisense oligonucleotide is 22 subunits in length and is 100% complementary to SEQ ID NO:6.

19. The method of claim 14, wherein the antisense oligonucleotide is attached to an arginine-rich polypeptide effective to enhance the uptake of the compound into host cells.

20. The method of claim 19, wherein the arginine-rich polypeptide has the sequence set forth in SEQ ID NO: 122.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.